Walk to Defeat ALS® Marks 25 Years of Honoring and Supporting People Living with ALS
For 25 years, the Walk to Defeat ALS® has brought together individuals and families impacted by ALS, offering hope, ...
Asia Asset Management2d
Has Bain bailed from tussle for Fuji Soft?
The unusually contentious bidding war between US private equity firms Bain Capital and KKR for Tokyo-listed Fuji Soft looks ...
ENDPOINTS NEWS4d
How Bain’s $3.3B deal for cen­turies-old Tan­abe Phar­ma came to fruition
About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...
FiercePharma4d
Fierce Pharma Asia—Astellas' investment focus; Mitsubishi Tanabe's buyout; Leqembi's 'expansion phase'
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Alpha-Synuclein Inhibitors Clinical Trial Pipeline As Novel And Extensive 22+ Therapies Likely To Enter In The Domain | Delveinsight
Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...
How this Veteran turned grief into purpose
ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...
manilatimes6d
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...